Form 4: Opus Genetics Director Cam Gallagher Acquires Shares and Options

Director Cam Gallagher of Opus Genetics, Inc. reports acquisition of common stock and stock options.

Summary

• On April 30, 2025, Cam Gallagher, a director of Opus Genetics, Inc., acquired 79,504 shares of common stock and stock options for 79,592 shares.
• The common stock was acquired at a price of $0 per share.
• Following the transaction, Gallagher directly owns 940,865 shares of common stock.
• The stock options have an exercise price of $0.95 and expire on April 29, 2035.
• The options and restricted stock units vest upon the earlier of the one-year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing insider transactions. The acquisition of shares by a director can be seen as a mildly positive signal.

Positives

• The acquisition of shares and options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the restricted stock units and options is contingent on continued service and occurs on the earlier of the one-year anniversary of the grant date or the day prior to the next annual meeting of stockholders.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of company insiders.

Stakeholder Impact

• Shareholders may view the director's increased stake as a positive signal.

Key Dates

Keywords

Opus Genetics, Director, Gallagher, Stock Options, Common Stock, Acquisition, Beneficial Ownership, Form 4